Sanofi SA

SNY · NYSE

$41.60−$0.36 (−0.86%)TodayMarket closed · Oct 23, 7:43 PM ET

Prev close $41.96

About SNY

Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 76,493 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.

Employees: 76,493
Headquarters: Paris, Ile-De-France
Listed: Jul 1, 2002
Sector: Health Care
Industry: Pharmaceuticals
Website: sanofi.com

Leadership

Sanofi SA executives
Name	Title	Since	Age
Frederic Oudea	—	—	61
Paul Hudson	—	2019	57
Francois-Xavier Roger	—	—	62
Natalie Bickford	—	—	54
Roy Papatheodorou	—	—	46
Prof. Dr. Houman Ashrafian	—	—	50
Olivier Charmeil	—	—	62
Audrey Derveloy	—	—	47
Brian Foard	—	—	51
Emmanuel Frenehard	—	—	52
Brendan O' Callaghan	—	—	63
Madeleine Roach	—	—	40
Thomas Triomphe	—	—	50
Julie Van Ongevalle	—	—	50
Christophe Babule	—	—	59
Wolfgang Laux	—	—	57
Barbara Lavernos	—	—	56
Tran Yann	—	—	59
Clotilde Delbos	—	—	57
Rachel Duan	—	—	54
Carole Ferrand	—	—	54
Lise Kingo	—	—	63
Jean-Paul Kress	—	—	60
Patrick Kron	—	—	71
Fabienne Lecorvaisier	—	—	62
Anne-Francoise Nesmes	—	—	53
John Sundy	—	—	63
Emile Voest	—	—	65
Antoine Yver	—	—	67
Thomas Larsen	—	2025	—

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.